Cargando…
Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients
BACKGROUND: Interstitial pneumonia (IP) is a common and fatal adverse effect of rituximab-containing immunochemotherapy in lymphoma patients. Following prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX), the clinical features, treatment, and risk factors for IP development remain la...
Autores principales: | Li, Cong, Lu, Fangxiao, Lei, Tao, Yu, Haifeng, Yang, Haiyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797998/ https://www.ncbi.nlm.nih.gov/pubmed/35117880 http://dx.doi.org/10.21037/tcr-20-988 |
Ejemplares similares
-
Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy
por: Li, Cong, et al.
Publicado: (2020) -
Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma
por: Yang, Jing, et al.
Publicado: (2022) -
A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy
por: Jungmann, Sven, et al.
Publicado: (2017) -
The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022) -
Interstitial pneumonia with autoimmune features: an additional risk factor for ARDS?
por: Grasselli, Giacomo, et al.
Publicado: (2017)